Download Files:
Vonafexor
$88 – $825
Products Details
Product Description
– Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research[1][2].
Web ID
– HY-109197
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C19H15Cl3N2O5S
References
– [1]Erken R, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28(12):1690-1698.|[2]Hui RW, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140.|[3]Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690.|[4]Fiorucci S,et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10.
CAS Number
– 1192171-69-9
Molecular Weight
– 489.76
Compound Purity
– 99.32
SMILES
– O=C(C1=CC2=C(Cl)C(N3CCN(S(=O)(C4=C(Cl)C=CC=C4Cl)=O)CC3)=CC=C2O1)O
Clinical Information
– Phase 2
Research Area
– Infection
Solubility
– DMSO : 83.33 mg/mL (ultrasonic)
Target
– FXR;HBV
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
